You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Aripiprazole
Aripiprazole is a high affinity dopamine D2 and 5-HT1A receptor partial agonist (Ki values are ~1.64 and 5.59 nM respectively). Also 5-HT2A antagonist (Ki = 8.7 nM). Suppresses morphine-induced emesis in vivo. Atypical antipsychotic.
Compound Libraries for Aripiprazole
Technical Data for Aripiprazole
|Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Aripiprazole
|Max Conc. mg/mL
|Max Conc. mM
Preparing Stock Solutions for Aripiprazole
The following data is based on the product molecular weight 448.39. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass
References for Aripiprazole
References are publications that support the biological activity of the product.
Davies et al (2004) Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 10 317 PMID: 15592581
Shiokawa et al (2007) Usefulness of the DA system-stabilizer aripipr. for reducing morphine-induced emesis. Eur.J.Pharmacol. 570 108 PMID: 17678644
If you know of a relevant reference for Aripiprazole, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Aripiprazole, Aripiprazole supplier, high, affinity, dopamine, D2, 5-ht1a, 5-ht2a, partial, agonists, antagonists, antipsychotic, Receptors, 5-HT1A, 5-HT2A, 5584, Tocris Bioscience
1 Citation for Aripiprazole
Citations are publications that use Tocris products. Selected citations for Aripiprazole include:
Marc et al (2020) Spinal Inhibition of GABAB Receptors by the Extracellular Matrix Protein Fibulin-2 in Neuropathic Rats. Front Cell Neurosci 14 214 PMID: 32765223
Do you know of a great paper that uses Aripiprazole from Tocris? Please let us know.
Reviews for Aripiprazole
There are currently no reviews for this product. Be the first to review Aripiprazole and earn rewards!
Have you used Aripiprazole?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.